Overview

Alloantibodies in Pediatric Heart Transplantation

Status:
Terminated

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the clinical outcomes of sensitized pediatric heart transplant recipients with a positive donor-specific cytotoxicity crossmatch and to compare this group with outcomes in nonsensitized heart transplant recipients.

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Isoantibodies
Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Rho(D) Immune Globulin
Tacrolimus